Kalif Eli's most recent trade in Teva- Pharmaceutical Industries Ltd. - ADR was a trade of 19,916 Restricted Share Units done . Disclosure was reported to the exchange on March 5, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Teva- pharma Ind Ltd (ADR) | Eli Kalif | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2026 | 19,916 | 59,748 | - | - | Restricted Share Units | |
| Teva- pharma Ind Ltd (ADR) | Eli Kalif | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2026 | 19,916 | 325,435 (0%) | 0% | - | Ordinary Shares | |
| Teva- pharma Ind Ltd (ADR) | Eli Kalif | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2026 | 53,175 | 53,175 | - | - | Restricted Share Units | |
| Teva- pharma Ind Ltd (ADR) | Eli Kalif | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2026 | 33,512 | 0 | - | - | Restricted Share Units | |
| Teva- pharma Ind Ltd (ADR) | Eli Kalif | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2026 | 33,512 | 282,268 (0%) | 0% | - | Ordinary Shares | |
| Teva- pharma Ind Ltd (ADR) | Eli Kalif | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2026 | 23,251 | 46,503 | - | - | Restricted Share Units | |
| Teva- pharma Ind Ltd (ADR) | Eli Kalif | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2026 | 23,251 | 305,519 (0%) | 0% | - | Ordinary Shares | |
| Teva- pharma Ind Ltd (ADR) | Eli Kalif | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2026 | 141,478 | 248,756 (0%) | 0% | - | Ordinary Shares | |
| Teva- pharma Ind Ltd (ADR) | Eli Kalif | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2026 | 141,478 | 0 | - | - | Restricted Share Units | |
| Teva- pharma Ind Ltd (ADR) | Eli Kalif | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2026 | 49,800 | 107,278 (0%) | 0% | - | Ordinary Shares | |
| Teva- pharma Ind Ltd (ADR) | Eli Kalif | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2026 | 49,800 | 49,802 | - | - | Restricted Share Units | |
| Teva- pharma Ind Ltd (ADR) | Eli Kalif | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 33.64 per share. | 26 Feb 2026 | 345,810 | 57,478 (0%) | 0% | 33.6 | 11,634,708 | Ordinary Shares |
| Teva- pharma Ind Ltd (ADR) | Eli Kalif | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2026 | 141,478 | 141,478 | - | - | Restricted Share Units | |
| Teva- pharma Ind Ltd (ADR) | Eli Kalif | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 17.08 per share. | 12 Jun 2025 | 55,775 | 403,288 (0%) | 0% | 17.1 | 952,464 | Ordinary Shares |
| Teva- pharma Ind Ltd (ADR) | Eli Kalif | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2025 | 79,664 | 79,664 | - | - | Restricted Share Units | |
| Teva- pharma Ind Ltd (ADR) | Eli Kalif | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2025 | 21,390 | 459,063 (0%) | 0% | - | Ordinary Shares | |
| Teva- pharma Ind Ltd (ADR) | Eli Kalif | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2025 | 21,390 | 0 | - | - | Restricted Share Units | |
| Teva- pharma Ind Ltd (ADR) | Eli Kalif | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2025 | 183,169 | 437,673 (0%) | 0% | - | Ordinary Shares | |
| Teva- pharma Ind Ltd (ADR) | Eli Kalif | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2025 | 183,169 | 0 | - | - | Restricted Share Units | |
| Teva- pharma Ind Ltd (ADR) | Eli Kalif | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2025 | 33,512 | 231,253 (0%) | 0% | - | Ordinary Shares | |
| Teva- pharma Ind Ltd (ADR) | Eli Kalif | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2025 | 33,512 | 33,512 | - | - | Restricted Share Units | |
| Teva- pharma Ind Ltd (ADR) | Eli Kalif | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2025 | 23,251 | 254,504 (0%) | 0% | - | Ordinary Shares | |
| Teva- pharma Ind Ltd (ADR) | Eli Kalif | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2025 | 23,251 | 69,754 | - | - | Restricted Share Units | |
| Teva- pharma Ind Ltd (ADR) | Eli Kalif | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 16.21 per share. | 28 Feb 2025 | 55,750 | 147,941 (0%) | 0% | 16.2 | 903,462 | Ordinary Shares |
| Teva- pharma Ind Ltd (ADR) | Eli Kalif | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 49,800 | 99,602 | - | - | Restricted Share Units | |
| Teva- pharma Ind Ltd (ADR) | Eli Kalif | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 49,800 | 197,741 (0%) | 0% | - | Ordinary Shares | |
| Teva- pharma Ind Ltd (ADR) | Eli Kalif | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2025 | 183,169 | 183,169 | - | - | Restricted Share Units | |
| Teva- pharma Ind Ltd (ADR) | Eli Kalif | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 13.52 per share. | 05 Mar 2024 | 77,550 | 203,691 (0%) | 0% | 13.5 | 1,048,119 | Ordinary Shares |
| Teva- pharma Ind Ltd (ADR) | Eli Kalif | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2024 | 52,320 | 259,854 (0%) | 0% | - | Ordinary Shares | |
| Teva- pharma Ind Ltd (ADR) | Eli Kalif | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2024 | 52,320 | 0 | - | - | Restricted Share Units | |
| Teva- pharma Ind Ltd (ADR) | Eli Kalif | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2024 | 21,387 | 21,390 | - | - | Restricted Share Units | |
| Teva- pharma Ind Ltd (ADR) | Eli Kalif | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2024 | 21,387 | 281,241 (0%) | 0% | - | Ordinary Shares | |
| Teva- pharma Ind Ltd (ADR) | Eli Kalif | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2024 | 93,005 | 93,005 | - | - | Restricted Share Units | |
| Teva- pharma Ind Ltd (ADR) | Eli Kalif | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2024 | 49,800 | 174,022 | - | - | Restricted Share Units | |
| Teva- pharma Ind Ltd (ADR) | Eli Kalif | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2024 | 49,800 | 174,022 (0%) | 0% | - | Ordinary Shares | |
| Teva- pharma Ind Ltd (ADR) | Eli Kalif | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2024 | 33,512 | 207,534 | - | - | Restricted Share Units | |
| Teva- pharma Ind Ltd (ADR) | Eli Kalif | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2024 | 33,512 | 207,534 (0%) | 0% | - | Ordinary Shares | |
| Teva- pharma Ind Ltd (ADR) | Eli Kalif | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 18,430 | 0 | - | - | Restricted Share Units | |
| Teva- pharma Ind Ltd (ADR) | Kalif Eli | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 18,430 | 124,222 (0%) | 0% | - | Ordinary Shares | |
| Teva- pharma Ind Ltd (ADR) | Eli Kalif | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2024 | 6,630 | 105,792 (0%) | 0% | - | Ordinary Shares | |
| Teva- pharma Ind Ltd (ADR) | Kalif Eli | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2024 | 6,630 | 0 | - | - | Restricted Share Units | |
| Teva- pharma Ind Ltd (ADR) | Eli Kalif | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2024 | 52,320 | 52,320 | - | - | Restricted Share Units |